Idelalisib (Zydelig) was once known as CAL-101 and was the most exciting new oral therapy in the CLL world, the shining morning star in the dawn of a new era of treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL).
Hodgkin lymphoma transformation is a rare type of Richter’s transformation in which CLL / SLL turns into Hodgkin lymphoma rather than DLBCL.
CLL cells express PD-1 when actively growing, and increased PD-1 expression may be an early sign of resistance to BTK inhibitor therapy.
During a 30-minute phone call, individuals have the opportunity to ask questions and get honest input from a fellow patient who has been through it before.
Patients with chronic lymphocytic leukemia (CLL) have an impaired immune system, which leads to a reduced ability to fight infections and other diseases.
Chronic lymphocytic leukemia (CLL) patients with abnormal bone health are at high risk for fragility fractures, which can occur with minimal trauma.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of a type of white blood cell called B-lymphocytes.
A newly published paper in Clinical Cancer Research found that when patients successfully treated with fixed-duration ibrutinib-venetoclax developed progressive disease, they had no acquired resistance mutations in BTK, BCL2, or PLCG2.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of
a type of white blood cell called B-lymphocytes.
© 2025 CLL Society. All Rights Reserved.
Legal | Privacy Policy | Corporate Giving Policy
Terms & Conditions | Report a Bug | Site Design
CLL Society Inc. is a patient–centric, physician–curated nonprofit organization focused on patient education, support, and research. Dedicated to addressing the unmet needs of the chronic lymphocytic leukemia (CLL) and related blood cancer communities, we explain the rapidly changing therapeutic landscape and the importance of clinical trials, support and build patient networks, engage in research, and educate providers and patients.
CLL Society is a registered 501(c)(3) tax-exempt nonprofit organization. All donations are tax-deductible to the greatest extent as allowed under federal law. CLL Society’s tax ID number is 46-4131354.
1454 Melrose Avenue, Ste. 1-247
Chula Vista, CA 91911
